Dadongnan (002263.SZ) released semi-annual results, with net profit of 9.8511 million yuan to mother, an increase of 24.07% over the previous year

According to Zhitong Finance App, Dadongnan (002263.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 676 million yuan, up 6.15% year on year; net profit attributable to shareholders of listed companies was 9.8511 million yuan, up 24.07% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 38.521 million yuan, down 14.64% year on year; basic earnings per share were 0.0052 yuan.

During the reporting period, the company continued to strengthen production safety management, actively lay out a differentiated product circuit, and optimize the product structure around high-value-added products; in segments such as new energy and high-end electronics, the share of high-performance product shipments increased steadily, driving an improvement in the gross margin of related products. At the same time, the company continued to expand the size of the R&D team, and R&D expenses increased by about 7.64% over the same period last year. Relying on a self-built R&D center platform, the subsidiary Hangzhou Hi-Tech added 1 invention patent and 3 utility model patents. The subsidiary Ningbo Vientiane is a “national manufacturing champion enterprise”. Currently, production capacity is operating at full capacity and order reserves are sufficient. Among them, orders in the UHV and military industries are growing well; the products have been exported to many countries and successfully developed the European market; the two imported coating production lines have completed the latest equipment configuration and are currently proceeding with installation and commissioning according to the plan. After production, the film industry chain will be extended to further increase the proportion of high-value-added products. Some of the company's R&D projects have completed small-batch trial production, and all performance indicators of the products have reached the intended targets.